A regimen of trastuzumab, paclitaxel, carboplatin and gemcitabine has favourable efficacy in advanced, HER2-positive urothelial cancer

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1591, 2007-01, pp. : 17-17

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Carboplatin increases efficacy of paclitaxel/trastuzumab in breast cancer

By  

Inpharma, Vol. 1, Iss. 1375, 2003-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

Preoperative trastuzumab, docetaxel and carboplatin therapy is effective for HER2-positive breast cancer

By  

Inpharma, Vol. 1, Iss. 1592, 2007-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

First-line therapy with trastuzumab plus paclitaxel and carboplatin may be active in patients with HER-2 over-expressing metastatic breast cancer

By  

Inpharma, Vol. 1, Iss. 1441, 2004-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Trastuzumab: In HER2-Positive Metastatic Gastric Cancer

By Croxtall Jamie D.   McKeage Kate  

Drugs, Vol. 70, Iss. 17, 2010-12 ,pp. : 2259-2267

Adis International

Access to resources Recommend Favorite

Carboplatin plus gemcitabine followed by paclitaxel is a well tolerated sequential regimen

By  

Inpharma, Vol. 1, Iss. 1305, 2001-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite